Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1990 Jan;61(1):151-5.
doi: 10.1038/bjc.1990.31.

Long-term somatic side-effects and morbidity in testicular cancer patients

Affiliations
Free PMC article

Long-term somatic side-effects and morbidity in testicular cancer patients

N Aass et al. Br J Cancer. 1990 Jan.
Free PMC article

Abstract

In order to evaluate long-term somatic morbidity after treatment for testicular cancer 149 patients with NED greater than or equal to 3 years answered a questionnaire. The patients had been treated with surgery only (32 patients, radiotherapy only (39 patients), cisplatin-based chemotherapy plus surgery (46 patients) or chemotherapy plus radiotherapy with or without surgery (32 patients). Raynaud-like phenomena were the most frequent side-effect occurring significantly more often after cisplatin-based chemotherapy than after surgery or radiotherapy (33/72 patients versus 5/68 patients). Peripheral sensory 'neuropathy' was reported by 18% of all the patients. Seventeen per cent and 11% complained of pulmonary symptoms and auditory symptoms, respectively. Gastrointestinal side-effects were more frequent after any type of cytotoxic therapy than after surgery only (34/47 patients versus 5/22 patients). Twenty-six patients had fathered children after treatment. About 80% of the patients were in full time wage-earning activity when they answered the questionnaire. In conclusion, 3-7 years after treatment for testicular cancer, 30-50% of the patients had minor somatic complaints whereas serious side-effects seldom occurred.

PubMed Disclaimer

References

    1. Int J Radiat Oncol Biol Phys. 1981 Oct;7(10):1413-7 - PubMed
    1. Ann Intern Med. 1981 Sep;95(3):288-92 - PubMed
    1. Ugeskr Laeger. 1982 Jan 25;144(4):267-73 - PubMed
    1. Ann Intern Med. 1984 May;100(5):704-13 - PubMed
    1. Radiother Oncol. 1984 Aug;2(2):93-9 - PubMed

Publication types